Behavioral, anti-dopaminergic, and prohypnotic effects of neuroleptics during and after prolonged treatment.
D000661:Amphetamine / Q000037:antagonists & inhibitors; D000818:Animals; D014150:Antipsychotic Agents / Q000494:pharmacology*; D001058:Apomorphine / Q000037:antagonists & inhibitors; D001522:Behavior, Animal / Q000187:drug effects*; D003024:Clozapine / Q000494:pharmacology; D004298:Dopamine / Q000502:physiology; D018492:Dopamine Antagonists; D004361:Drug Tolerance; D005260:Female; D006220:Haloperidol / Q000494:pharmacology; D006993:Hypnotics and Sedatives; D008297:Male; D051379:Mice; D009043:Motor Activity / Q000187:drug effects; D010080:Oxazoles / Q000494:pharmacology; D010879:Piperazines / Q000494:pharmacology; D011954:Receptors, Dopamine / Q000187:drug effects; D013997:Time Factors
D014150:Antipsychotic Agents; D018492:Dopamine Antagonists; D006993:Hypnotics and Sedatives; D010080:Oxazoles; D010879:Piperazines; D011954:Receptors, Dopamine; C015599:LR 511; D000661:Amphetamine; D003024:Clozapine; D006220:Haloperidol; D001058:Apomorphine; D004298:Dopamine